The present invention relates to the utilization of ADAMTS3 metalloprotease. More specifically, the present invention relates to a method of producing fully processed mature VEGF-C polypeptide by a cell and a method of cleaving VEGF-C polypeptides. Furthermore, the present invention relates to different uses of ADAMTS3, ADAMTS3 inhibitors or compositions comprising ADAMTS3 or ADAMTS3 inhibitors, and a method of treating a lymphatic disorder. In addition, the invention relates to a method of producing VEGF-Cbinding molecules.
|Publication Year||30 Jul 2015|
|Publication status||Published - 30 Jul 2015|
|MoE publication type||H1 Granted patent|
Fields of Science
- 3111 Biomedicine